Date receipt dossier
EudraCT number
2014-003111-10
Company / Sponsor
Catapult Cell Therapy
Phase
I/II
Treated organism
Humans
Indication category
Cancer therapy
Disease
Acute myeloid leukemia and myelodysplastic syndromes in adults
Therapeutic approach
Immunotherapy
Genetic modification
Expression of the Wilms' tumour antigen 1 (WT1)- specific T cell receptor (TCR)
Method of transfer of nucleic acid of interest
Retroviral vectors
Administered biological material
Autologous T-cells transduced with retroviral vectors expressing WT1-specific TCR
Route of administration
Intravenous
Locations in Belgium
UZ Leuven, AZ Sint-Jan Brugge-Oostende
Type of procedure
Contained use only
Current status
Authorized